



## Berkshire West Area Prescribing Committee Policy Statement

<b>Drug Name</b>	Lisdexamphetamine (Elvanse®)
<b>Indication under review</b>	Treatment for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate and/or atomoxetine treatment is considered clinically inadequate.
<b>Policy No:</b>	APC 010
<b>Date of issue, date re-issued:</b>	September 2013, November 2015
<b>Review Date:</b>	November 2018
<b>Policy Statement:</b> Lisdexamphetamine is a treatment option for the management of ADHD when previous response to methylphenidate in a subgroup of patients is considered inadequate.	
<b>Traffic Light Status</b>	<b>Amber</b>
<b>Key Points considered:</b> <ul style="list-style-type: none"><li>• The available evidence shows that improvements from baseline in the ADHD symptom scale was statistically significantly greater in children and young people who received lisdexamfetamine dimesylate or modified-release methylphenidate compared with those who received placebo.</li><li>• The preparation is once daily and would be given before school (there removing the need to keep a controlled drug on the school premises)</li><li>• This treatment is suitable for shared care and the risk of overdose is included in Shared Care Protocol.</li></ul> A treatment pathway has been agreed (to encompass methylphenidate, atomoxetine and lisdexamphetamine including who prescribes what and when etc. <b>See</b> 'Prescribing arrangements for the use of methylphenidate, dexamphetamine, lisdexamfetamine and atomoxetine in children with ADHD (attention deficit hyperactivity disorder) with transition to adult services in Berkshire	
<b>References:</b> <ol style="list-style-type: none"><li>1. NRP104-201 - Biederman et al, Biol Psychiatry 2007;62:970-976<sup>7</sup></li><li>2. NRP104-301 - Biederman et al, Clin Ther 2007;29:450-463<sup>8</sup></li><li>3. SPD489-311 - Wigal et al. Child &amp; Adolesc Psychiatry Mental Health. 2009;3:17</li></ol>	
<b>Date 1<sup>st</sup> taken to APC:</b>	4 <sup>th</sup> September 2013
<b>Date re-ratified by MOC on Behalf of the Board:</b>	18 <sup>th</sup> November 2015